Sanofi Reports meta-analysis Data for Lebrikizumab in Head and neck cancer

Sanofi today announced meta-analysis results for lebrikizumab in patients with head and neck cancer. The study demonstrated that lebrikizumab demonstrates sustained efficacy compared to standard of care or placebo. These results provide important insights into the treatment of head and neck cancer and support the continued development of lebrikizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.